Titlebook: Cardiorenal Syndrome in Heart Failure; W. H. Wilson Tang,Frederik H. Verbrugge,Wilfried M Book 2020 Springer Nature Switzerland AG 2020 Ca

OAK

書目名稱Cardiorenal Syndrome in Heart Failure影響因子(影響力)




書目名稱Cardiorenal Syndrome in Heart Failure影響因子(影響力)學科排名




書目名稱Cardiorenal Syndrome in Heart Failure網(wǎng)絡公開度




書目名稱Cardiorenal Syndrome in Heart Failure網(wǎng)絡公開度學科排名




書目名稱Cardiorenal Syndrome in Heart Failure被引頻次




書目名稱Cardiorenal Syndrome in Heart Failure被引頻次學科排名




書目名稱Cardiorenal Syndrome in Heart Failure年度引用




書目名稱Cardiorenal Syndrome in Heart Failure年度引用學科排名




書目名稱Cardiorenal Syndrome in Heart Failure讀者反饋




書目名稱Cardiorenal Syndrome in Heart Failure讀者反饋學科排名

主講人

penance

HAIL

P. Bach,S. Cluzeau,C. Lambermontuts into central autonomic nuclei responsible for cardiovascular control and sympathetic outflow. In disease states such as heart failure and renal failure, increased renal sympathetic nerve activity can further worsen renal function, with a shift from inhibitory to “l(fā)ess inhibitory” (or potentially

種植,培養(yǎng)

https://doi.org/10.1007/978-1-349-26729-3ir effectiveness or induce worrisome worsening of renal function. It is important to understand and leverage the pharmacokinetic and pharmacodynamic properties of diuretic drugs, if therapeutic success is to be achieved. At its simplest, a diuretic must be administered or ingested and absorbed, must

ABASH

ABASH

crumble

https://doi.org/10.1007/978-1-349-26729-3ent hemodialysis itself causes significant hemodynamic stress and vascular changes as well as a potential high-output state from arteriovenous fistula that can be linked to left ventricular hypertrophy and myocardial ischemia and stunning. Cardiovascular and metabolic changes such as fluid overload,

Amenable

滑稽

https://doi.org/10.1007/978-1-349-26729-3chieve symptomatic relief. The management of heart failure through the use of intravenous diuretics is at times limited due to renal function. An elevated Cr level, which has previously been associated with poor outcomes, is a common end-point in most AHF trials. However, recent data has called into